Top Molecular Diagnostics Companies

The global molecular diagnostics industry is a vital segment of the life sciences and healthcare spaces as millions of patients and healthcare providers rely on advanced diagnostic technologies to diagnose, monitor, and treat illness. The industry provides this capability through the discovery and design of molecular diagnostics, PCR tests, next generation sequencing platforms, and specific tests for certain cancers, infectious diseases, and hereditary diseases. The global medical diagnostics market is a major contributor to economic growth within the United States by creating thousands of jobs associated with industries such as manufacturing, clinical services, research & development, and regulatory.  Each entity affiliated with molecular diagnostics supports many jobs associated with distribution and laboratory services and healthcare delivery.  This page discusses several key molecular diagnostics companies, their product lines, areas of innovation, and market shares.

Industry Overview

According to SkyQuest Technology Molecular Diagnostics Market  size is estimated to reach USD 33.7 billion by 2032. The rising demand for early disease diagnosis, particularly in cancer, infectious diseases, and genetic diseases, is expected to increase the compound annual growth rate (CAGR) of the instruments segment during the forecast period. For the diagnosis of diseases such as cancer, HIV, and genetic disorders, methods such as PCR, NGS, and microarrays are considered important.

Top 10 Global Molecular Diagnostics Companies

1. F. Hoffmann-La Roche Ltd.

Roche is a global leader in the field of molecular diagnostics, providing a broad range of PCR tests and next generation sequencing systems. Their products are relied upon for oncology, infectious diseases, and genetic testing. For Roche's diagnostics division, the year 2024 saw the molecular diagnostics market represent a significant portion of CHF 68.7 billion. The company is enlarging its premises and exhibiting further commitment to the development of diagnostic technologies by investing $550 million into expansion efforts in Indianapolis.

2. Hologic, Inc.

Hologic has established its abilities in molecular diagnostics in women's health focusing on assays for HPV, STIs, and breast cancer. Research on this topic has advanced, and Hologic's molecular diagnostics business- excluding COVID-19 tests- brought in revenues of $289 million in the third quarter of 2025, a 6.0% increase compared to the previous year during this same time period. This advancement in growth clearly demonstrates Hologic's capabilities in the molecular diagnostics market as related to women's health.

 3. Abbott Laboratories

Abbott is heavily investing in molecular diagnostics, including $1 billion to improve transfusion diagnostics manufacturing. Abbott is now ready to penetrate an approximate $1 billion market for molecular nucleic acid blood and plasma testing. Abbott's intention to expand diagnostically shows that the company targets urgent health needs through state-of-the-art molecular technology.

4. Illumina, Inc.

Illumina specializes in next-generation sequencing (NGS) technologies which are important for genetic research and clinical diagnostics.  As a result of their advocacy efforts, Illumina has expanded health insurance coverage for genetic testing by an additional 100 million people in 2024, for a total of covering 1.4 billion lives.  This unique program illustrates Illumina's commitment to enhancing access to genomic testing and integrating it into healthcare systems so everyone can benefit from landmark advancements in genomics.   

5. Thermo Fisher Scientific, Inc.

Thermo Fisher's molecular diagnostics solutions include reagents, equipment, and laboratory-developed tests (LDTs).  Their technologies are used to diagnose a range of targets including proteins, pathogens, DNA, and RNA, making their technologies versatile for diagnostic purposes.  In 2024, Thermo Fisher demonstrated a strong position in the molecular diagnostics industry through its wide variety of consumables and diagnostic kit offerings in their healthcare market channel.  

6. BioMerieux

bioMérieux is the worldwide leader in syndromic molecular diagnostics and microbiology with greater than 70% market share globally. In 2023, the company generated €3.7 billion in revenue with >90% of that revenue generated outside of France. Their diagnostic solutions are key players in diagnosing microorganisms responsible for directing infectious diseases worldwide.

7. QIAGEN

QIAGEN offers a broad portfolio of molecular testing solutions, which includes digital solutions, consumables and instruments. QIAGEN estimates its total addressable market across its portfolio of molecular diagnostics exceeds an annual value of $11 billion. QIAGEN intends to develop technologies, establish partnerships with researchers, and acquire companies in adjacent markets to expand the services that it provides in molecular diagnostics.

8. BD (Becton) and Company

BD is a significant player in the diagnostics market, particularly in relation to the development of diagnostic tools for infectious disease and cancer. BD announced its intention to merge its $3 billion-plus revenue, Biosciences & Diagnostic Solutions, with Waters Corporation, a merger announced in 2025 for $17.5 billion, creating a company with a combined total addressable market of $40 billion. This strategy is likely to improve BD's capacity and opportunity for product expansion in the molecular diagnostics industry.

9. Grifols S.A.

Grifols focuses on therapies derived from plasma and diagnostic solutions, including screening blood with molecular diagnostics. An important share of the company's €7.3 billion sales revenues in 2024 can be ascribed to the diagnostic solutions sector at Grifols. Grifols has a commitment to developing diagnostic solutions that maximize global safety and effectiveness for plasma-derived therapies and blood transfusions.

10. Bio-Rad Laboratories, Inc.

Bio-Rad has a large number of instruments and reagents that are molecular diagnostics for clinical applications and for research. Most of the $3.7 billion that Bio-Rad received in income in 2024 was from the testing division-Diagnosis. Bio-Rad's strong positioning in molecular diagnostics is exemplified by the company’s use of genetic analyses in identifying infectious disease, with a broad spectrum of diagnostic use cases.

Other Leading Global Molecular Diagnostics Companies

• Sysmex Corporation
• Quidel Corporation
• Biocartis
• DiaSorin
• Myriad Genetics
• Revvity
• MDxHealth
• OncoCyte Corporation
• Danaher
• Siemens Healthineers AG

Conclusion

The ten molecular diagnostics companies identified in this report exemplify the size and breadth of the global diagnostics and healthcare sector. They provide a wide breadth of solutions, in all instances ranging from well-known diagnostic technologies provided by companies such as Roche and Abbott to specialized products from Illumina, QIAGEN, and bioMérieux. These companies are jointly influencing the global molecular diagnostics market. This is giving rise to the increasing demand for rapid and accurate diagnostic solutions that can satisfy the requirements of a diverse patient population. Together, they will also influence personalized medicine, enhance the detection of diseases, and trigger innovations.